Repros Therapeutics Inc. (RPRX) Shares Down 7.2%
Shares of Repros Therapeutics Inc. (NASDAQ:RPRX) traded down 7.2% during mid-day trading on Tuesday . The stock traded as low as $0.50 and last traded at $0.50. 821,118 shares traded hands during trading, a decline of 27% from the average session volume of 1,121,700 shares. The stock had previously closed at $0.54.
Separately, Laidlaw lowered shares of Repros Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, July 21st.
The firm’s 50-day moving average is $0.43 and its 200 day moving average is $0.50. The company’s market cap is $18.85 million.
Repros Therapeutics (NASDAQ:RPRX) last issued its quarterly earnings results on Monday, August 14th. The biotechnology company reported ($0.08) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.22) by $0.14. The company had revenue of $0.01 million for the quarter. Repros Therapeutics had a negative net margin of 56,062.07% and a negative return on equity of 412.64%. On average, equities research analysts predict that Repros Therapeutics Inc. will post ($1.07) EPS for the current fiscal year.
A hedge fund recently raised its stake in Repros Therapeutics stock. Allegis Investment Advisors LLC boosted its position in Repros Therapeutics Inc. (NASDAQ:RPRX) by 8.9% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 398,792 shares of the biotechnology company’s stock after acquiring an additional 32,602 shares during the period. Allegis Investment Advisors LLC owned 1.49% of Repros Therapeutics worth $183,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 14.51% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Repros Therapeutics Inc. (RPRX) Shares Down 7.2%” was first posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at https://theolympiareport.com/2017/10/31/repros-therapeutics-inc-rprx-shares-down-7-2.html.
Repros Therapeutics Company Profile
Repros Therapeutics, Inc is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis.
Receive News & Ratings for Repros Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repros Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.